Please assess the completion status of the following clinical trial:

Trial Title: ADX10059 Migraine Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 to 65 years~* History of migraine~* Aged ≤ 50 years at onset of migraine history~Exclusion Criteria:~* Cluster headache or chronic migraine headaches~* Currently uses, or within 3 months of Screening, has used: sodium valproate or topiramate and any other drugs used specifically for migraine prophylaxis, for example beta-blockers, calcium channel blockers, tricyclic antidepressants, selective serotonin reuptake inhibitors~* Unable to distinguish migraine headache from tension and other types of headache~* Current history of psychiatric disorder requiring regular medication~* Known history of alcohol abuse~* Known clinically significant allergy or known hypersensitivity to drugs~* History of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ADX10059 25 mg (Type: EXPERIMENTAL): Weeks 1-2: once daily Weeks 3-12: twice daily
- ADX10059 50 mg (Type: EXPERIMENTAL): Weeks 1-2: once daily Weeks 3-12: twice daily
- ADX10059 100 mg (Type: EXPERIMENTAL): Weeks 1-2: once daily Weeks 3-12: twice daily
- ADX10059 Matching Placebo (Type: PLACEBO_COMPARATOR): Weeks 1-2: once daily Weeks 3-12: twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).